Skip to content
Cardiovascular healthEvidence review4 min read

Each 5 mm Hg systolic drop with BP drugs linked to about 10% fewer major cardiac events

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. · Lancet (London, England) · 2021 · Original paper ↗

Key takeaway

Across 48 randomised trials with 344,716 participants, lowering systolic blood pressure by 5 mm Hg with medication cut the hazard of a major cardiovascular event (HR 0.91 without prior cardiovascular disease, 0.89 with it), including at normal or high-normal starting pressures. The trials were published between 1972 and 2013 with a median follow-up of 4.15 years, so long-term and modern-practice effects are not addressed.

Study design

Evidence review

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

It is unclear whether drug treatment to lower blood pressure helps people whose pressure is already normal or high-normal, with or without existing cardiovascular disease. The authors pooled individual participant data from randomised trials to see how treatment effects on major cardiovascular events vary with starting systolic pressure.

Who and how

Individual participant-level meta-analysis of 48 randomised trials comparing blood pressure-lowering drugs with placebo or other drug classes, or more versus less intensive treatment, each with at least 1000 person-years of follow-up per group. Trials solely in heart failure or short-term acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects were analysed by prior cardiovascular disease status and across seven systolic blood pressure categories (from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (fatal and non-fatal stroke, myocardial infarction or ischaemic heart disease, or heart failure causing death or hospital admission), by intention to treat. Funding: British Heart Foundation, UK National Institute for Health Research and Oxford Martin School.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Data covered 344,716 participants (157,728 with previous cardiovascular disease, 186,988 without). After a median 4.15 years, 42,324 participants (12.3%) had at least one major cardiovascular event.
  2. 2
    Each 5 mm Hg reduction in systolic pressure was associated with a hazard ratio of 0.91 (95% CI 0.89-0.94) in people without previous cardiovascular disease and 0.89 (95% CI 0.86-0.92) in those with it.
  3. 3
    Event rates per 1000 person-years were 31.9 (comparator) versus 25.9 (intervention) without previous cardiovascular disease, and 39.7 versus 36.0 with it.
  4. 4
    There was no reliable evidence that the treatment effect differed by baseline cardiovascular disease status or systolic pressure category. Before treatment, 19.8% of those with previous disease and 8.0% of those without had systolic pressure below 130 mm Hg.

Limits & uncertainty

  1. 1
    Trials spanned 1972 to 2013, and background care and drug use have changed since then.
  2. 2
    Median follow-up was 4.15 years, so effects over longer periods are not shown.
  3. 3
    The finding that benefit does not vary by baseline pressure comes from subgroup analyses, which have less power than the overall analysis.
  4. 4
    The abstract does not report side effects, which matter when treating people with normal pressure. This reading is based on the abstract only.

What to take from it

The analysis supports the idea that, in trial populations, the proportional benefit of lowering blood pressure with medication is similar whether or not someone has had cardiovascular disease, and the authors argue the focus should be on reducing cardiovascular risk. Whether to start or change blood pressure medication is a decision for a person and their clinician.

Reading your own data

A validated upper-arm blood pressure cuff is the relevant home tool: measure at the same time, seated and rested, and look at averages over days to weeks rather than single readings. Wrist-worn estimates are not equivalent to cuff readings.

How to read this evidence

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.

Methods

We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat.

Findings

Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 mm Hg in participants without previous cardiovascular disease (n=186 988). There was substantial spread in participants' blood pressure at baseline, with 31 239 (19·8%) of participants with previous cardiovascular disease and 14 928 (8·0%) of individuals without previous cardiovascular disease having a systolic blood pressure of less than 130 mm Hg. The relative effects of blood pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction. After a median 4·15 years' follow-up (Q1-Q3 2·97-4·96), 42 324 participants (12·3%) had at least one major cardiovascular event. In participants without previous cardiovascular disease at baseline, the incidence rate for developing a major cardiovascular event per 1000 person-years was 31·9 (95% CI 31·3-32·5) in the comparator group and 25·9 (25·4-26·4) in the intervention group. In participants with previous cardiovascular disease at baseline, the corresponding rates were 39·7 (95% CI 39·0-40·5) and 36·0 (95% CI 35·3-36·7), in the comparator and intervention groups, respectively. Hazard ratios (HR) associated with a reduction of systolic blood pressure by 5 mm Hg for a major cardiovascular event were 0·91, 95% CI 0·89-0·94 for partipants without previous cardiovascular disease and 0·89, 0·86-0·92, for those with previous cardiovascular disease. In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by baseline cardiovascular disease status or systolic blood pressure categories.

Interpretation

In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high-normal blood pressure values. These findings suggest that a fixed degree of pharmacological blood pressure lowering is similarly effective for primary and secondary prevention of major cardiovascular disease, even at blood pressure levels currently not considered for treatment. Physicians communicating the indication for blood pressure lowering treatment to their patients should emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself.

Funding

British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.

Sources & attribution

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration.

Lancet (London, England) · 2021-05-01

DOI: 10.1016/s0140-6736(21)00590-0 ↗PubMed · 33933205 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Observational meta-analysis

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

In-depth explainersRead study →
·Trial meta-analysis

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

In-depth explainersRead study →
·Randomised trial

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

In-depth explainersRead study →
·Validation study/review

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

In-depth explainersRead study →
Cardiovascular health →